- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Second-generation inhibitors of Bruton tyrosine kinase ; volume:9 ; number:1 ; day:2 ; month:9 ; year:2016 ; pages:1-7 ; date:12.2016
Journal of hematology & oncology ; 9, Heft 1 (2.9.2016), 1-7, 12.2016
- Creator
-
Wu, Jingjing
- Contributor
-
Liu, Christina
Tsui, Stella T.
Liu, Delong
SpringerLink (Online service)
- DOI
-
10.1186/s13045-016-0313-y
- URN
-
urn:nbn:de:1111-201610013616
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wu, Jingjing
- Liu, Christina
- Tsui, Stella T.
- Liu, Delong
- SpringerLink (Online service)
Other Objects (12)
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report
Newer Tyrosine Kinase Inhibitors for CML
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
The effects of tyrosine kinase inhibitors in pancreatic cancer
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report
Newer Tyrosine Kinase Inhibitors for CML
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
The effects of tyrosine kinase inhibitors in pancreatic cancer
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report
Newer Tyrosine Kinase Inhibitors for CML
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML